On December 31, 2024, Veru Inc., a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm, as well as other co-investors subject to adjustment as set forth in the purchase agreement. Wilson Sonsini Goodrich & Rosati advised Clear Future, Inc. on the transaction.
The Wilson Sonsini team that advised Clear Future included:
Corporate
Jake Gatof
Mark Bass
Reilly Clark
Victoria Burch
Katie Gu
Trademark
Aaron Hendelman
FDA/Regulatory
Eva Yin
Data, Privacy, and Cybersecurity
Michael O’Brien
Technology Transactions
Robert Parr
Andrew Poling
Graham Hendrick
Erica Hur
Regina McLeod
Hale Melnick
Christopher Murray
Mary O’Brien
Anna Weber
For more information, please see Veru’s press release.